Literature DB >> 26891035

Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting.

Simon Schneider1, Christoph D Spinner, Salvatore Cassese, Dominik Promny, Alexander Hapfelmeier, Robert A Byrne, Marcus Baumann, Hans Jäger, Eva Steinlechner, Karl-Ludwig Laugwitz, Adnan Kastrati.   

Abstract

OBJECTIVES: The life expectancy of HIV-infected patients has recently been increasing. Although the mortality and morbidity associated with AIDS is decreasing, those associated with cardiovascular diseases and percutaneous coronary intervention (PCI) are receiving greater attention. Only limited data regarding coronary restenosis are available in these patients.
DESIGN: In this prospective, systematic angiographic follow-up study, we enrolled HIV patients who underwent PCI for de-novo lesions and subsequent routine angiographic follow-up for 6-8 months. Angiographic restenosis was defined as stenosis of at least 50% of the in-segment area.
METHODS: Univariate and multivariate analyses were performed to evaluate restenosis and its predictors.
RESULTS: Between May 2002 and March 2014, 47 patients with HIV underwent PCI in two high-volume centers in Munich, Germany. Of these patients, 41 with 131 de-novo lesions underwent invasive surveillance. One-quarter of the lesions treated subsequently presented with restenosis. Univariate analysis indicated that CD8 T-cell levels (P = 0.006), serum cholesterol (P = 0.042) and low-density lipoprotein-cholesterol (P = 0.042) levels at baseline, total number of stents (P = 0.047), and C-reactive protein level (P = 0.001) at follow-up were associated with restenosis. Multivariate analysis indicated that CD8 T-cell levels (P = 0.006) and persistent C-reactive protein elevation at 6-month follow-up (P = 0.00013) were independent predictors of restenosis.
CONCLUSION: Inflammation, represented by CD8 T-cell levels, and persistent C-reactive protein elevation are independent predictors of angiographic restenosis and should therefore be closely monitored in HIV patients undergoing PCI.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26891035     DOI: 10.1097/QAD.0000000000001063

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

Review 1.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

2.  Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.

Authors:  Iria Bravo; Hortensia Álvarez; Ana Mariño; Bonaventura Clotet; José Moltó
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

Review 3.  Epidemiology of ischemic heart disease in HIV.

Authors:  Virginia A Triant; Steven K Grinspoon
Journal:  Curr Opin HIV AIDS       Date:  2017-11       Impact factor: 4.283

4.  Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.

Authors:  Sergio Serrano-Villar; Kunling Wu; Peter W Hunt; Judith J Lok; Raquel Ron; Talía Sainz; Santiago Moreno; Steven G Deeks; Ronald J Bosch
Journal:  EBioMedicine       Date:  2022-05-26       Impact factor: 11.205

5.  Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV.

Authors:  Arjun Sinha; Yifei Ma; Rebecca Scherzer; Sophia Hur; Danny Li; Peter Ganz; Steven G Deeks; Priscilla Y Hsue
Journal:  J Am Heart Assoc       Date:  2016-12-20       Impact factor: 5.501

6.  Aggressive In-Stent Restenosis after Carotid Artery Stenting in a Patient with HIV Infection.

Authors:  Dae Yeon Kim; Bum Sik Chin; Jang Hyun Baek; Jong Yun Lee; Jusun Moon
Journal:  J Clin Neurol       Date:  2021-01       Impact factor: 3.077

7.  Assessing the differential impact of chronic CMV and treated HIV infection on CD8+ T-cell differentiation in a matched cohort study: is CMV the key?

Authors:  Matthias C Mueller; Winfried V Kern; Susanne Usadel; Marie-Christin Pauly; Toni Cathomen; Ulrich Salzer
Journal:  AIDS Res Ther       Date:  2021-06-30       Impact factor: 2.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.